Alpine BioVentures

Alpine BioVentures is a venture capital firm dedicated to investing in innovative life sciences companies. The firm focuses on identifying and supporting bold scientific ideas with the potential to transform patient care, particularly in areas such as cancer, autoimmune conditions, and orphan diseases. By licensing cutting-edge technologies and collaborating closely with scientific inventors, Alpine BioVentures aims to create impactful companies that address unmet medical needs.

The firm's investment strategy encompasses a wide range of stages, from seed funding to late-stage investments, including Series A, Series B, growth, and pre-IPO rounds. Alpine BioVentures has a strong geographical focus on the United States, seeking opportunities to partner with companies that are developing groundbreaking therapies and medical solutions. The firm is particularly interested in sectors such as biotechnology, pharmaceuticals, diagnostics, and medical devices, with an emphasis on areas like immunology, oncology, neurology, cardiology, infectious diseases, regenerative medicine, genomics, proteomics, and bioinformatics.

Alpine BioVentures has a proven track record of enabling disruptive scientific advancements. Notably, the firm founded and seed-funded Alpine Immune Sciences in 2015, leading to its public listing on NASDAQ under the ticker symbol 'ALPN' in 2017. Additionally, Alpine BioVentures co-invested in Mavupharma, which was acquired by AbbVie in 2019. These successes underscore the firm's commitment to partnering with visionary scientists and entrepreneurs to bring transformative medical innovations to market.